Delhi HC restrains Cipla from using Gluco-C or Gluco-D trademarks

Zydus argued that Cipla started branding its Glucose product under Gluco C ++ and Gluco D ++, in order to create confusion in the minds of customers

Cipla, Cipla logo, Cipla headquarters
Zydus Wellness Products had filed a lawsuit against Cipla Health (Representational image)
BS Web Team New Delhi
2 min read Last Updated : Jul 04 2023 | 1:42 PM IST
The Delhi High Court (HC) on Monday passed an interim order restraining Prolyte, a brand owned by Cipla, to stop using the trademarks Gluco-C or Gluco-D, according to a report published by Moneycontrol.com.

Zydus Wellness Products, which manufactures and sells the energy drinks GLUCON-C and GLUCON-D, had filed a lawsuit against Cipla Health alleging that Cipla Health's trademarks were deceptively similar to its registered trademarks.

Cipla Health contested the lawsuit, arguing that Zydus Wellness's registrations for the trademarks GLUCON-C and GLUCON-D were invalid and were liable to be removed from the Register of Trademarks. Zydus said that Cipla had merely deleted an ‘N’ and Gluco-D is phonetically and visually similar to GLUCON-D. The firm said that even the hyphen between GLUCON and D has been replicated.

Zydus argued that Cipla also adopted the typography of a vertically slanting indented edge with the words ‘instant energy’ on a yellow background. Zydus said that it is a market leader in the energy drink segment, with its GLUCON-D Tangy Orange taking a market share of 74 per cent. The brand GLUCON-D has, therefore, become synonymous with the company.

The firm argued that Cipla started branding its Glucose product under Gluco C ++ and Gluco D ++, in order to create confusion in the minds of customers into believing an association between the products.

Cipla argued that the trademarks GLUCON-C and GLUCON-D are descriptive of the kind, quality, and intended purpose of the products they are used for. As such, the firm argued that these trademarks are not distinctive and cannot be registered as trademarks. Cipla hence contended that there could be no action from such entities for infringement of trademarks.

The court said that the word Prolyte prefixed to Gluco-C and Gluco-D does not distinguish it from GLUCON-D as ‘Gluco’ is the main ingredient in the name. The court therefore held that Gluco-D is similar to GLUCON-D and therefore, it infringes on Zydus’ registered trademark. The court further said that Zydus cannot argue that Cipla used the look and feel of GLUCON-D to fool customers as many health drinks have adopted a similar brand strategy for their products.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :High CourtDelhi High CourtCiplaZydus WellnessBS web teampharma sctorsZydus HealthcarePharma Companies

First Published: Jul 04 2023 | 1:42 PM IST

Next Story